ArticleEuropean journal of public health2026
Aligning health, industry, and innovation through public procurement.
Article in European journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This article examines how public procurement of pharmaceuticals can serve as a tool to advance both access to medicines and industrial development, in line with the Health in All Policies (HiAP) and Health for All Policies (HfIAP) agendas. We draw on four illustrative, purposefully selected cases-the pneumococcal Advance Market Commitment, emergency procurement of the Ebola vaccine, Operation Warp Speed for the accelerated production of coronavirus disease 2019 (COVID-19) vaccines, and Brazil's Partnerships for Productive Development. Through configurative analysis, we identify distinct procurement models and assess their contributions to health and industrial objectives. The analysis highlights several procurement models: anticipatory, reactive, emergency-driven, innovation-enabling, and capability-building. These cases demonstrate how procurement can generate co-benefits across Sustainable Development Goals (SDGs) 3 (health) and 9 (industry, innovation, infrastructure), while also revealing implementation gaps and structural constraints. Realizing the potential of procurement as a dual health-industrial tool requires linking it to capability-building, tailoring instruments to local and industrial contexts, and confronting structural asymmetries that limit national ownership. By treating procurement not as an administrative task but as an industrial strategy, governments can better operationalize HiAP/HfIAP and make progress toward more equitable and sustainable health innovation systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.